CBSA and other members of the Council of State Bioscience Associations (CSBA) have submitted a letter to the Centers for Medicare & Medicaid Services (CMS) expressing our deep concern with a recent proposed rule that seeks to reinterpret the Medicaid “Best Price” calculation for the Medicaid Drug Rebate Program (MDRP). The proposal would make manufacturers aggregate, or “stack,” all discounts and rebates received throughout their supply chain when determining the “Best Price,” which establishes what state Medicaid programs pay for drugs. An October 27th letter from ten Senate Finance Committee Republicans agrees that this proposal puts patients at risk of losing access to life-saving medicines and vaccines.
Concerns with the Proposed Rule
In summary, we are concerned that this proposed rule would place a substantial burden on biotechnology manufacturers and…
Click here to view original post
